Comment on “Influence of Age on the Development of Stress Hyperglycemia During First‐Onset ST‐Elevation Myocardial Infarction” Authors: Muhammad Mussab Aman, Andaleeb Ikram, Najib Ullah Tokhi, Muhammad Meeran Umar, Nawazish Ali Published: 2026 Dear editor, We have read with great interest the paper by Hon Jen Wong and colleagues regarding the effect of age on stress hyperglycemia in STEMI patients who had never been diagnosed with diabetes before. In this big national registry study of 8,779 patients, the researchers offer us valuable information about stress hyperglycemia being more common in older people, but with a relatively stronger relationship between stress hyperglycemia and mortality in young people. It helps to give stress hyperglycemia ratio (SHR) another aspect in terms of age 1 . First, an important aspect of these results is the difference between the concepts of relative and absolute risk. Despite the fact that the hazard ratios for stress hyperglycemia became lower and lower with increasing age, the absolute mortality rates significantly increased from 1.14% at 30 days and 3.43% at 10 years in the group of patients aged less than 40 years to 23.33% and 58.40%, respectively, in the group of patients aged 80 years or older. Therefore, the reduction in the relative hazard with increasing age does not necessarily mean reducing the clinical significance of this phenomenon in elderly patients. The prognostic significance of SHR may differ according to the level of baseline risk 2 . Second, a clinically important finding is the disparity in treatment regimens between those who have and do not have stress hyperglycemia. The individuals who have stress hyperglycemia had a lesser likelihood of being on beta‐blockers, ACE‐inhibitors/angiotensin receptor blockers, and lipid‐lowering agents while admitted to the hospital. The patients also had less usage of dual antiplatelet therapy. While the possible reason why this was seen might be their hemodynamic instability, it can also be seen as an effect on their care based on their clinical evidence‐based care, which might account for the higher mortality rate seen. Of note, the models of mortality that have been published take into consideration the clinical characteristics including the presence of heart failure, but do not include these treatment variables. Age‐dependent differences in treatment would therefore be another way in which the association between SHR and mortality could occur 3 . Third, the results of the study must be interpreted more as an indication of risk stratification than a reason to support glucose‐lowering treatment guided by SHR. The fact that there is such a strong prognostic correlation in young patients is very interesting in clinical terms; however, whether these patients will receive any benefit from a special treatment regimen remains unclear. Thus, prospective trials may examine if SHR can identify those patients who have different effects from a certain intervention 4 . The work of Hon Jen Wong and colleagues offers useful data regarding the fact that the clinical significance of stress hyperglycemia in patients following STEMI is dependent on age. The use of continuous interaction and treatment‐based factors in future research could potentially determine whether the relationship is influenced by biological variability, differing risk factors, or different treatments. This could aid in developing the clinical use of SHR beyond being just a useful marker to a predictive one. DISCLOSURE The authors declare that they have no conflict of interest. Approval of the research protocol: N/A. Informed consent: N/A. Registry and the registration no. of the study/trial: N/A. Animal studies: N/A.